| ||||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
![]() |
Recurrent upper respiratory tract infections |
![]() |
|
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
A number of different thymus preparations are commercially available. However, whether any of them have the same effects as Thymomodulin, which is not available in the United States, is still unknown. The recommended amount of thymus extract varies according to the type of preparation.
No side effects or adverse reactions have been reported with the use of thymus preparations.
Are there any drug
interactions?
Certain medicines may interact with thymus extracts. Refer to drug interactions for a list of those medicines.
1. Cazzola P, Mazzanti P, Bossi G. In vivo modulating effect of a calf thymus acid lysate on human T lymphocyte subsets and CD4+/CD8+ ratio in the course of different diseases. Curr Ther Res 1987;42:1011–7.
2. Kouttab NM, Prada M, Cazzola P. Thymomodulin: Biological properties and clinical applications. Med Oncol Tumor Pharmacother 1989;6:5–9 [review].
3. Fiocchi A, Borella E, Riva E, et al. A double-blind clinical trial for the evaluation of the therapeutic effectiveness of a calf thymus derivative (Thymomodulin) in children with recurrent respiratory infections. Thymus 1986;8:831–9.
4. Galli L, de Martino M, Azzari C, et al. Preventive effect of thymomodulin in recurrent respiratory infections in children. Pediatr Med Chir 1990;12:229–32.
5. Vettori G, Lazzaro A, Mazzanti P, Cazzola P. Prevention of recurrent respiratory infections in adults. Minerva Med 1987;78:1281–9.
6. Longo F, Lepore L, Agosti E, Panizon F. Evaluation of the effectiveness of thymomodulin in children with recurrent respiratory infections. Pediatr Med Chir 1988;10:603–7.
7. Maiorano V, Chianese R, Fumarulo R, et al. Thymomodulin increases the depressed production of superoxide anion by alveolar macrophages in patients with chronic bronchitis. Int J Tissue React 1989;11:21–5.
8. Garagiola U, Buzzetti M, Cardella E. Immunological patterns during regular intensive training in athletes: quantification and evaluation of a preventive pharmacological approach. J Int Med Res 1995;23:85–95.
9. Wysocki J, Wierusz-Wysocka B, Wykretowicz A, Wysocki H. The influence of thymus extracts on the chemotaxis of polymorphonuclear neutrophils (PMN) from patients with insulin-dependent diabetes mellitus (IDD). Thymus 1992;20:63–7.
10. Calsini P, Mocchegiani E, Fabris N. The pharmacodynamics of thymomodulin in elderly humans. Drugs Exp Clin Res 1985;11:671–4.
11. Braga PC, Dal Sasso M, Maci S, et al. Restoration of polymorphonuclear leukocyte function in elderly subjects by thymomodulin. J Chemother 1994;6:354–9.
12. Galli M, Crocchiolo P, Negri C, et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (Thymomodulin): preliminary results. Drugs Expt Clin Res 1985;11:665–9.
13. Bortolotti F, Cadrobbi P, Criverllaro C, et al. Effect of an orally administered thymic derivative, Thymodulin, in chronic type B hepatitis in children. Curr Ther Res 1988;43:67–72.
14. Valesini G, Barnaba V, Benvenuto R, et al. A calf thymus lysate improves clinical symptoms and T-cell defects in the early stages of HIV infection: second report. Eur J Cancer Clin Oncol 1987;23:1915–9.
15. Kouttab NM, Prada M, Cazzola P. Thymomodulin: biological properties and clinical applications. Med Oncol Tumor Pharmacother 1989;6:5–9 [review].
16. Kang SD, Lee BH, Yang JH, Lee CY. The effects of calf-thymus extract on recovery of bone marrow function in anticancer chemotherapy. New Med J 1985;28:11–5.
17. Schulof RS. Thymic peptide hormones: basic properties and clinical applications in cancer. Crit Rev in Oncol Hematol 1985;3:309–76 [review].
18. Meneses G, Delgado MA, Perez-Machado A, et al. Thymostimulin increases natural cytotoxic activity in patients with breast cancer. Int J Immunopharmacol 1997;19:187–93.
19. Skotnicki AB. Thymic hormones and lymphokines. Drug Today 1989;25:337–62 [review].
20. Ernst E. Thymus therapy for cancer? A criteria-based, systematic review. Eur J Cancer 1997;33:531–5 [review].
21. Vasilopoulos G, Porwit A, Lauren L, et al. The effect of a calf thymus acid lysate on bone marrow cell growth in vitro. Immunopharmacol Immunotoxicol 1988;10:523–36.
22. Skotnicki AB. Thymic hormones and lymphokines. Drug Today 1989;25:337–62 [review].
23. Cazzola P, Mazzanti P, Bossi G. In vivo modulating effect of a calf thymus acid lysate on human T lymphocyte subsets and CD4+/CD8+ ratio in the course of different diseases. Curr Ther Res 1987;42:1011–7.
24. Kouttab NM, Prada M, Cazzola P. Thymomodulin: biological properties and clinical applications. Med Oncol Tumor Pharmacother 1989;6:5–9 [review].
25. Marzari R, Mazzanti P, Cazzola P, Pirodda E. Perennial allergic rhinitis: prevention of the acute episodes with Thymomodulin. Minerva Med 1987;78:1675–81.
26. Genova R, Guerra A. A thymus extract (thymomodulin) in the prevention of childhood asthma. Pediatr Med Chir 1983;5:395–402.
27. Bagnato A, Brovedani P, Comina P, et al. Long-term treatment with thymomodulin reduces airway hyperresponsiveness to methacholine. Ann Allergy 1989;62:425–8.
28. Fiocchi A, Grasso U, Travaglini P, et al. A double blind clinical trials on the effectiveness of a thymic derivative (Thymomodulin) in the treatment of children with atopic dermatitis. Int J Immunother 1987;3:279–84.
29. Cavagni G, Piscopo E, Rigoli E, et al. Food allergy in children: an attempt to improve the effects of the elimination diet with an immunomodulating agent (thymomodulin). A double-blind clinical trial. Immunopharmacol Immunotoxicol 1989;11:131–42.
30. Genova R, Guerra A. Thymomodulin in management of food allergy in children. Int J Tissue React 1986;8:239–42.
31. Miric M, Vasiljevic J, Bojic M, et al. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 1996;75:596–601.
32. Miric M, Miskovic A, Brkic S, et al. Long-term follow-up of patients with myocarditis and idiopathic dilated cardiomyopathy after immunomodulatory therapy. Immunol Med Microbiol 1994;10:65–74.
| |||||||